NasdaqGS - Nasdaq Real Time Price USD

Legend Biotech Corporation (LEGN)

45.30 +0.88 (+1.98%)
At close: April 26 at 4:00 PM EDT
45.30 0.00 (0.00%)
After hours: April 26 at 5:10 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
285,143.00
285,143.00
117,005.00
68,826.00
75,000.00
Cost of Revenue
144,214.00
144,214.00
65,363.00
--
--
Gross Profit
140,929.00
140,929.00
51,642.00
68,826.00
75,000.00
Operating Expense
580,414.00
580,414.00
507,262.00
461,113.00
301,793.00
Operating Income
-439,485.00
-439,485.00
-455,620.00
-392,287.00
-226,793.00
Net Non Operating Interest Income Expense
32,693.00
32,693.00
-2,614.00
71.00
-1,279.00
Other Income Expense
-113,326.00
-113,326.00
12,510.00
-14,980.00
-80,213.00
Pretax Income
-520,118.00
-520,118.00
-445,724.00
-407,196.00
-308,285.00
Tax Provision
-1,864.00
-1,864.00
625.00
-3,614.00
-41,912.00
Net Income Common Stockholders
-518,254.00
-518,254.00
-446,349.00
-403,582.00
-266,373.00
Diluted NI Available to Com Stockholders
-518,254.00
-518,254.00
-446,349.00
-403,582.00
-266,373.00
Basic EPS
-2.94
-2.94
-2.80
-2.86
-2.26
Diluted EPS
-2.94
-2.94
-2.80
-2.86
-2.26
Basic Average Shares
176,082.71
176,082.71
159,041.96
140,851.65
118,152.62
Diluted Average Shares
176,082.71
176,082.71
159,041.96
140,851.65
118,152.62
Total Expenses
724,628.00
724,628.00
572,625.00
461,113.00
301,793.00
Net Income from Continuing & Discontinued Operation
-518,254.00
-518,254.00
-446,349.00
-403,582.00
-266,373.00
Normalized Income
-433,507.35
-433,507.35
-467,830.50
-397,437.80
-266,470.63
Interest Income
54,487.00
54,487.00
8,182.00
971.00
2,930.00
Interest Expense
21,794.00
21,794.00
10,796.00
900.00
195.00
Net Interest Income
32,693.00
32,693.00
-2,614.00
71.00
-1,279.00
EBIT
-498,324.00
-498,324.00
-434,928.00
-406,296.00
-308,090.00
EBITDA
-477,873.00
-477,873.00
-416,536.00
-392,379.00
-298,157.00
Reconciled Cost of Revenue
144,214.00
144,214.00
65,363.00
--
--
Reconciled Depreciation
20,451.00
20,451.00
18,392.00
13,917.00
9,933.00
Net Income from Continuing Operation Net Minority Interest
-518,254.00
-518,254.00
-446,349.00
-403,582.00
-266,373.00
Total Unusual Items Excluding Goodwill
-85,087.00
-85,087.00
21,503.00
-6,200.00
113.00
Total Unusual Items
-85,087.00
-85,087.00
21,503.00
-6,200.00
113.00
Normalized EBITDA
-392,786.00
-392,786.00
-438,039.00
-386,179.00
-298,270.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-340.35
-340.35
21.50
-55.80
15.37
12/31/2020 - 6/5/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BGNE BeiGene, Ltd.
153.58
+3.38%
 
BPMC Blueprint Medicines Corporation
93.00
+2.50%
 
GMAB Genmab A/S
28.15
+2.51%
 
APLS Apellis Pharmaceuticals, Inc.
49.86
+4.03%
 
ALNY Alnylam Pharmaceuticals, Inc.
143.31
-0.28%
 
ALXO ALX Oncology Holdings Inc.
16.86
-0.06%
 
ASND Ascendis Pharma A/S
135.90
-0.75%
 
APGE Apogee Therapeutics, Inc.
47.13
+2.77%
 
KRYS Krystal Biotech, Inc.
156.88
+0.77%
 
CYTK Cytokinetics, Incorporated
65.34
+0.83%